Predictors of response to treatment with Actovegin (cas 63748-11-8) for 6 months in patients with type 2 diabetes and symptomatic polyneuropathy
-
Add time:07/12/2019 Source:sciencedirect.com
AimsTo evaluate two definitions of response and the predictive value of baseline covariates for response to Actovegin (cas 63748-11-8) treatment in type 2 diabetic patients with symptomatic diabetic sensorimotor polyneuropathy (DSPN).
We also recommend Trading Suppliers and Manufacturers of Actovegin (cas 63748-11-8). Pls Click Website Link as below: cas 63748-11-8 suppliers
Prev:Asymmetric synthesis of di- and trisubstituted pyrrolidinones via zirconium-mediated intramolecular coupling of N-3-alkenyl carbamates
Next:Pleiotropic neuroprotective and metabolic effects of Actovegin (cas 63748-11-8)'s mode of action) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Highly purified calf hemodialysate (Actovegin (cas 63748-11-8)®) may improve endothelial function by activation of proteasomes: A hypothesis explaining the possible mechanisms of action07/15/2019
- A prospective, randomized, multi-center trial to investigate Actovegin (cas 63748-11-8) in prevention and treatment of acute oral mucositis caused by chemoradiotherapy for nasopharyngeal carcinoma07/14/2019
- Pleiotropic neuroprotective and metabolic effects of Actovegin (cas 63748-11-8)'s mode of action07/13/2019
